New players in chronic lung disease identified at the European Respiratory Society International Congress in Paris 2018 : From microRNAs to extracellular vesicles
(2018) In Journal of Thoracic Disease 10. p.2983-2987- Abstract
- Since the first description of microRNAs (miRNAs) in 1993 (1) a large and growing number of studies has explored their roles across a variety of biomedical research disciplines, including lung biology. According to GENCODE (version 27) (2), 1881 of the >7,500 human small non-coding RNAs are miRNAs. These 20–25 nucleotide-long, regulatory RNAs are involved in the translational regulation of gene expression principally via binding to miRNA recognition elements largely in the 3' untranslated regions of target mRNAs. Upon binding they can induce mRNA degradation, deadenylation or inhibition of their translation, leading to decreased target gene expression (3). Originally described to play important roles in developmental biology, miRNAs... (More)
- Since the first description of microRNAs (miRNAs) in 1993 (1) a large and growing number of studies has explored their roles across a variety of biomedical research disciplines, including lung biology. According to GENCODE (version 27) (2), 1881 of the >7,500 human small non-coding RNAs are miRNAs. These 20–25 nucleotide-long, regulatory RNAs are involved in the translational regulation of gene expression principally via binding to miRNA recognition elements largely in the 3' untranslated regions of target mRNAs. Upon binding they can induce mRNA degradation, deadenylation or inhibition of their translation, leading to decreased target gene expression (3). Originally described to play important roles in developmental biology, miRNAs have since been found to have significant roles in a multitude of biological processes. Expression levels of miRNAs vary greatly between cells and tissues, and aberrant levels of miRNA are associated with many diseases in humans. In fact, these non-coding RNA molecules are now recognized as major regulators in the development and progression of various chronic lung diseases, including cystic fibrosis (CF), idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD) and asthma (4-9). (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3c10ff6f-bb91-4e77-8455-aa3630271d48
- author
- Burgy, Olivier ; Fernandez, Elena Fernandez ; Enes, Sara Rolandsson LU ; Königshoff, Melanie ; Greene, Catherine M. and Bartel, Sabine
- organization
- publishing date
- 2018
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of Thoracic Disease
- volume
- 10
- pages
- 2983 - 2987
- publisher
- AME Publishing Company
- external identifiers
-
- scopus:85053258843
- pmid:30310685
- ISSN
- 2072-1439
- DOI
- 10.21037/jtd.2018.08.20
- language
- English
- LU publication?
- yes
- id
- 3c10ff6f-bb91-4e77-8455-aa3630271d48
- date added to LUP
- 2018-10-15 12:46:50
- date last changed
- 2024-09-03 03:44:38
@article{3c10ff6f-bb91-4e77-8455-aa3630271d48, abstract = {{Since the first description of microRNAs (miRNAs) in 1993 (1) a large and growing number of studies has explored their roles across a variety of biomedical research disciplines, including lung biology. According to GENCODE (version 27) (2), 1881 of the >7,500 human small non-coding RNAs are miRNAs. These 20–25 nucleotide-long, regulatory RNAs are involved in the translational regulation of gene expression principally via binding to miRNA recognition elements largely in the 3' untranslated regions of target mRNAs. Upon binding they can induce mRNA degradation, deadenylation or inhibition of their translation, leading to decreased target gene expression (3). Originally described to play important roles in developmental biology, miRNAs have since been found to have significant roles in a multitude of biological processes. Expression levels of miRNAs vary greatly between cells and tissues, and aberrant levels of miRNA are associated with many diseases in humans. In fact, these non-coding RNA molecules are now recognized as major regulators in the development and progression of various chronic lung diseases, including cystic fibrosis (CF), idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD) and asthma (4-9).}}, author = {{Burgy, Olivier and Fernandez, Elena Fernandez and Enes, Sara Rolandsson and Königshoff, Melanie and Greene, Catherine M. and Bartel, Sabine}}, issn = {{2072-1439}}, language = {{eng}}, pages = {{2983--2987}}, publisher = {{AME Publishing Company}}, series = {{Journal of Thoracic Disease}}, title = {{New players in chronic lung disease identified at the European Respiratory Society International Congress in Paris 2018 : From microRNAs to extracellular vesicles}}, url = {{http://dx.doi.org/10.21037/jtd.2018.08.20}}, doi = {{10.21037/jtd.2018.08.20}}, volume = {{10}}, year = {{2018}}, }